REG - BSF Enterprise PLC - Agreement

BSF EnterpriseAnnouncement

10/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nRSJ5222Qa&default-theme=true

RNS Number : 5222Q  BSF Enterprise PLC  10 July 2025

 

 

London,  10 July 2025

 

 

BSF Enterprise PLC

 

Kerato signs Exclusive Worldwide Option Agreement

 

BSF Enterprise PLC (LSE:BSFA) (the "Company") a leading innovator in
tissue-engineered materials is pleased to announce that its wholly owned
subsidiary Kerato Limited has signed an exclusive worldwide option agreement
with Université de Montréal for the intellectual property supporting LiQD
Cornea, a novel dropwise treatment for corneal damage (LiQD Cornea).

This agreement provides exclusive, worldwide rights to the patent within the
field of ophthalmology, significantly strengthening Kerato's IP portfolio and
reinforcing its leadership in corneal tissue engineering and regenerative
solutions.

Over 13 million people worldwide are currently waiting for a corneal
transplant, with demand far exceeding donor availability. The global corneal
transplant market is expected to reach USD 1.86 billion by 2033, driven by the
rising incidence of corneal disease and the urgent need for scalable,
tissue-engineered alternatives. LiQD Cornea is designed to provide a simple,
scalable, and effective alternative to donor cornea transplantation. The
option agreement complements Kerato's existing proprietary know-how and IP in
corneal tissue engineering, which together underpin the development of an
accessible, bioengineered solution to address a growing global burden of
corneal blindness.

The agreement underpins the next key milestones on Kerato's roadmap to
commercialisation

·    First-in-human clinical study; regulatory preparations are under way,
with study initiation planned for early 2027.

·    Regulatory and commercial readiness; activities to support clinical
trial approvals and future market access are progressing in parallel with
ongoing product development.

Together, these milestones will enable Kerato to complete clinical trials and
regulatory approvals, while the agreement further strengthens the company's
intellectual property and commercial portfolio, laying the foundation for
future product launch.

"This agreement is a key step on our strategic roadmap," said Sarah
Greenhalgh, Co-founder and Managing Director of Kerato. "It allows us to
progress with confidence toward clinical validation and commercialisation, and
builds on our interdisciplinary expertise in tissue engineering,
ophthalmology, and medical device development."

The agreement marks a critical step in Kerato's strategy to bring LiQD Cornea
to market as a transformative treatment for corneal blindness.

 

It also enhances the business case for investment by private funds into Kerato
as a stand-alone entity. Any proposed investment into Kerato will be
non-dilutive to investors in BSF and will help position it to accelerate the
development and release of LIQD Cornea to the world market

 

 

Contact Information For further information, please
visit: www.bsfenterprise.com (http://www.bsfenterprise.com/)

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 BSF Enterprise PLC

 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)
 Damon Heath                                     0207 186 9000

 Isabella Pierre                                 0207 186 9927

 ISIN of the Ordinary Shares is GB00BHNBDQ51.

 SEDOL Code is BHNBDQ5.

 

About BSF Enterprise PLC

BSF Enterprise PLC (BSF) develops and commercialises cutting-edge
tissue-engineered solutions, including lab-grown leather, cultivated meat, and
corneal repair technologies. By leveraging its proprietary scaffold-free
platform, BSF aims to deliver sustainable alternatives to traditional
materials and meet global demand for environmentally responsible innovations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDZGMNFGNGKZG